Skip to Primary Content
Skip to Footer
home
about
products & pipeline
Clinical Trials
Publications
newsroom
investors
Stock Information
Press Releases
Events & Presentations
SEC Filings
ESG
Financial Information
partners
careers
Afrezza.com
818.661.5000
careers
partners
investors
Stock Information
Press Releases
Events & Presentations
SEC Filings
ESG
Financial Information
newsroom
products & pipeline
Clinical Trials
Publications
about
News & Events
April 1, 2020
Pediatric Afrezza® (insulin human) Inhalation Powder
Indication Expansion
T1 and T2 diabetes mellitus (pediatrics)
previous post
next post
×